Florida Pilot Brings a Robotic Blood Draw Machine to Clinics

BayCare plans to become the first health system in Florida to let a robot draw blood. The Clearwater-based system said it will pilot Aletta, an image-guided robotic blood draw device from the Dutch company Vitestro, at two of its busiest laboratory sites. Patients will be able to choose the robotic blood draw when they book an appointment or walk in, and anyone who prefers a human hand can still ask for a phlebotomist.

The pilot is scheduled to start late next year and run for up to two years. BayCare will place one device at its Suncoast Medical Office Building and another at its HealthHub site in Bardmoor, and during the trial it will track how accurate the draws are and how patients and staff feel about the experience. Donna Lynch, BayCare's vice president of Laboratory, said the system wants to see whether the device can improve the blood draw experience while giving laboratory teams another tool. The announcement came in a company statement on Monday.

How the draw works

Aletta uses imaging to find a suitable vein, then handles the steps a phlebotomist would normally do by hand. The needle stays out of the patient's view during the procedure, according to Vitestro, and a phlebotomist stays in the room to supervise. At BayCare, one staff member will oversee two devices at a time, while laboratory team members prepare the machines and handle cleaning and disposal between patients.

Patients aged twenty-one and older will be eligible to choose the robotic option. The device is meant to work alongside BayCare's existing laboratory services, and the system said the pilot will help it decide whether to expand the technology. For patients who dread needles, the draw itself changes: the machine does the searching, and a trained person stays close by.

Why regulators signed off

Federal regulators authorized Aletta last August through a pathway for novel low-to-moderate-risk devices with no comparable device already on the market. The authorization covers adults in outpatient settings under the oversight of a supervisor trained in phlebotomy, and it does not cover blood donation. In clinical testing at three hospitals in the Netherlands, the robotic blood draw device recorded a first-stick success rate of 94.5 percent, according to Vitestro, and the results were published in a peer-reviewed journal.

The clearance matters beyond one Florida pilot because blood draws are among the most common procedures in medicine, and clinics across the country report shortages of trained phlebotomists. A single supervisor can oversee up to three robotic blood draw machines at once under the federal authorization, which could ease waits at busy outpatient labs. Aletta was already in use in European hospitals before the United States authorization, after earlier approval for use in Europe.

BayCare is the largest not-for-profit academic health care system in West Central Florida, according to the system, and the pilot will run at two of its busiest laboratory patient service centers. During the trial, BayCare will evaluate robotic blood draw accuracy, patient and staff satisfaction, and operational performance before deciding what comes next. The results will show whether patients accept a machine at the moment they usually brace for a needle, and whether clinics can move people through faster without losing the human check at the end of the process.

What patients should expect

Booking will work the same way it does now, with one extra choice. When scheduling an appointment, patients can select the robotic option if it is available, and walk-in visitors can ask for it on arrival. The machine guides the patient to position an arm, then a button press starts the session. If the device cannot find a suitable vein, it stops, and the supervising phlebotomist steps in.

The broader question is staffing. Laboratory leaders have said for years that trained phlebotomists are hard to hire, and routine blood work still depends on a person with steady hands and a free slot on the schedule. A machine that handles the physical stick does not read results or interpret them, and it does not decide which tests a patient needs. What robotic blood draw changes is the first step of the process, the one patients tend to remember most.

Vitestro developed Aletta as the first standalone system for robotic blood draw, and the company has raised fresh funding this year to speed up deployment. A Danish hospital has ordered devices for its own wards, according to the company, and more health systems are watching the Florida pilot as an early test of whether patients will accept the change. BayCare's answer, expected after the trial runs its course, will help decide how fast robotic blood draw spreads beyond a single state.

Sources: BayCare announcement via GlobeNewswire and Medscape coverage of the FDA authorization.